BeOne Medicines reports Q4 revenue of $1.2B (+15% YoY) and FY2025 revenue of $4.5B (+12% YoY), driven by BRUKINSA sales.

This announcement provides investors and stakeholders with a comprehensive overview of BeOne Medicines' financial health and operational performance for the fiscal year 2025. Key metrics such as revenue growth, profitability, and R&D investment will offer insights into the company's market position and its ability to fund ongoing pipeline development and commercial expansion, particularly for key products like BRUKINSA.